AstraZeneca Launches Phase III VECTRA-1 Trial for AZD2265 (²²⁵Ac-PSMA) in Metastatic Castration-Resistant Prostate Cancer
May 29, 2026 07:42
CST Updated
11:44
AstraZeneca
Pharmaceutical Technology Research and Development Provider
Hengrui Pharma
Innovative and High-Quality Pharmaceutical Developer
BeOne
Developer of Molecular Targeted and Immune Anti-Tumor Drugs
Innovent
High-end Biologics Developer